Patents Assigned to Aunova Medchem LLC
  • SOLUBILITY FOR TARGET COMPOUNDS
    Publication number: 20170066778
    Abstract: The present disclosure relates to compounds having an improved solubility thereby increasing their bioavailability, lower dosages, etc. The target compounds, may include but are not limited to, macrophage migration inhibitory factor (MIF) inhibitors, epidermal growth factor receptor (EGRF) inhibitors, kinase inhibitors and prodrugs of alpha4 beta1 and alpha4 beta7 integrin antagonists.
    Type: Application
    Filed: August 29, 2016
    Publication date: March 9, 2017
    Applicant: Aunova Medchem LLC
    Inventor: Achyutharao Sidduri